Table 1.
1985 – 88 | Extensive studies on brain ischemia/perfusion insult (IRI) in gerbils |
Demonstrated salicylate trapping of hydroxyl free radicals in brain IRI | |
Established time dependent IRI-mediated brain damage in hippocampus and forebrain | |
1988 | Basic discovery that PBN protected in experimental stroke-Dec 1988 |
Discovery patented, basic studies continued, made many attempts to license to companies | |
1992–1993 | Centaur Pharmaceutical, Inc. founded March 1992 |
Angel investments made possible, CEO hired | |
Company hires employees, begins to conduct experiments to add value | |
Explores extent of intellectual property and revise patents for commercial development | |
1995 | Centaur and Astra make co-development relationship – June 1995 |
Ramp-up studies in stroke, medicinal chemistry for other indications | |
1996 | NXY059 chosen as candidate drug for stroke |
1996 – 2002 | NXY059 undergoes extensive toxicology and tested in several clinical phase I and 2 trials |
2002 lead |
Renovis, Inc buys Centaur assets and moves clinical trials forward with AstraZeneca taking |
2003 | NXY059 Phase 3 SAINT-1 efficacy trial began in May 2003 |
2005 | SAINT-1 trial shows efficacy in 1700 patients – May 2005 |
SAINT-2 trial begins for 3200 patients – July 2005 | |
2006 | Analysis of combined SAINT-1 and SAINT-2 trials showed NXY059 not effective- Oct 2006 |